Y-mAbs Therapeutics announces results of annual shareholder meeting votes

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a biotechnology company with a market capitalization of $192 million and a strong financial health rating according to InvestingPro, held its annual meeting of stockholders on Friday, July 11, where shareholders voted on three proposals, according to a statement released Tuesday based on a filing with the Securities and Exchange Commission.

For the first proposal, shareholders elected David N. Gill as Class I director. Gill will serve until the company’s 2028 annual meeting of stockholders or until a successor is elected and qualified, or upon earlier death, resignation, or removal. The vote tally for Gill’s election was 18,926,572 shares for and 11,924,775 shares withheld, with 3,133,377 broker non-votes.

The second proposal, to ratify the appointment of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, was approved. The results were 32,884,437 shares for, 1,097,151 shares against, and 3,136 shares abstaining.

The third proposal, a non-binding advisory vote on the compensation of the company’s named executive officers as disclosed in the proxy statement, was also approved. The votes were 27,011,027 shares for, 3,838,565 shares against, 1,755 shares abstaining, and 3,133,377 broker non-votes.

Y-mAbs Therapeutics is incorporated in Delaware and is headquartered in Princeton, New Jersey. The company’s common stock is listed on the Nasdaq Global Select Market under the symbol YMAB.

This information is based on a press release statement and the company’s SEC filing.

In other recent news, Y-mAbs Therapeutics reported its first-quarter 2025 earnings, surpassing expectations with an earnings per share (EPS) of -$0.12, compared to the forecast of -$0.1911. The company’s revenue reached $20.9 million, slightly above the forecast of $20.84 million, marking an 8% year-over-year increase driven by international sales. Clear Street maintained a Buy rating on Y-mAbs, setting a price target of $17.00, following the company’s Radiotherapeutics Research and Development Event. During this event, Y-mAbs shared updates on its Specific Antibody Drug Conjugates with Alpha-emitting radioisotopes (SADA) technology and future development plans. Meanwhile, H.C. Wainwright adjusted its price target for Y-mAbs to $11.00 from $12.00, while maintaining a Buy rating, citing upcoming developments that could expand the company’s drug pipeline. These developments include updates on the Phase 1/2 trial of Y-mAbs’ GD2-SADA program, which is expected to provide significant insights at the company’s R&D day in May 2025. Y-mAbs continues to focus on advancing its clinical trials and expanding its market presence globally, with ongoing efforts to strengthen its radiopharmaceutical platform.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.